United Therapeutics (UTHR)’s Chairman & CEO Martine Rothblatt Unloaded 43024 shares of the Company; QUALCOMM (QCOM) Had 17 Bullish Analysts

United Therapeutics Corporation (NASDAQ:UTHR) Logo

Among 37 analysts covering Qualcomm Inc. (NASDAQ:QCOM), 17 have Buy rating, 2 Sell and 18 Hold. Therefore 46% are positive. Qualcomm Inc. had 139 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity with “Buy” on Monday, June 26. Susquehanna maintained the shares of QCOM in report on Tuesday, January 16 with “Buy” rating. As per Thursday, July 21, the company rating was maintained by Cowen & Co. The company was maintained on Thursday, July 21 by Goldman Sachs. The firm earned “Equal-Weight” rating on Thursday, November 10 by Morgan Stanley. The rating was maintained by Bernstein with “Hold” on Thursday, November 2. The stock has “Hold” rating by Stifel Nicolaus on Wednesday, March 7. The stock has “Buy” rating by Canaccord Genuity on Thursday, July 20. Argus Research maintained it with “Buy” rating and $70 target in Thursday, January 14 report. The rating was downgraded by CLSA on Monday, January 23 to “Underperform”. See QUALCOMM Incorporated (NASDAQ:QCOM) latest ratings:

26/03/2018 Broker: Susquehanna Rating: Buy New Target: $68.0000 Maintain
20/03/2018 Broker: Bank of America Rating: Buy New Target: $75.0
19/03/2018 Broker: Morgan Stanley Rating: Underweight New Target: $55 Maintain
15/03/2018 Broker: Deutsche Bank Rating: Hold New Target: $60 Maintain
13/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $86.0 Maintain
07/03/2018 Broker: Stifel Nicolaus Rating: Hold Downgrade
19/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $80.0 Maintain
13/02/2018 Broker: Charter Equity Rating: Hold Maintain
05/02/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $82.0 Maintain
01/02/2018 Broker: Northland Capital Rating: Buy New Target: $75.0 Maintain

The stock increased 1.30% or $0.71 during the last trading session, reaching $55.41. About 8.48 million shares traded. QUALCOMM Incorporated (NASDAQ:QCOM) has declined 3.21% since March 30, 2017 and is downtrending. It has underperformed by 14.76% the S&P500.

Since October 27, 2017, it had 0 insider purchases, and 5 sales for $6.10 million activity. Another trade for 356 shares valued at $19,117 was made by ROGERS ALEXANDER H on Friday, October 27. THOMPSON JAMES H had sold 50,126 shares worth $3.14M. $2.81M worth of QUALCOMM Incorporated (NASDAQ:QCOM) was sold by GROB MATTHEW S.

QUALCOMM Incorporated develops, designs, makes, and markets digital communications services and products in China, South Korea, Taiwan, the United States, and internationally. The company has market cap of $82.03 billion. The firm operates through three divisions: Qualcomm CDMA Technologies ; Qualcomm Technology Licensing (QTL); and Qualcomm Strategic Initiatives (QSI). It currently has negative earnings. The QCT segment develops and supplies integrated circuits and system software based on code division multiple access (CDMA), orthogonal frequency division multiple access (OFDMA), and other technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products.

Investors sentiment decreased to 0.83 in 2017 Q4. Its down 0.02, from 0.85 in 2017Q3. It worsened, as 89 investors sold QUALCOMM Incorporated shares while 518 reduced holdings. 160 funds opened positions while 346 raised stakes. 1.11 billion shares or 0.73% more from 1.10 billion shares in 2017Q3 were reported. Whittier Trust Of Nevada reported 24,253 shares. Washington Tru Com holds 720 shares. Insight 2811 stated it has 16,755 shares. Putnam Ltd Liability Com accumulated 22,035 shares or 0% of the stock. The New York-based Tig Advsr Limited Company has invested 3.89% in QUALCOMM Incorporated (NASDAQ:QCOM). Apg Asset Mngmt Nv has invested 0.09% in QUALCOMM Incorporated (NASDAQ:QCOM). Us National Bank De owns 1.42M shares or 0.28% of their US portfolio. Parus Finance (Uk), United Kingdom-based fund reported 140,022 shares. Bennicas And Assocs Incorporated accumulated 12,525 shares or 0.7% of the stock. Finemark National Bank And invested in 0.09% or 21,459 shares. Parametric Port Ltd Liability Co has invested 0.26% in QUALCOMM Incorporated (NASDAQ:QCOM). Moreover, Horrell Management Incorporated has 0.03% invested in QUALCOMM Incorporated (NASDAQ:QCOM) for 750 shares. Wellington Mngmt Grp Llp invested 0.65% of its portfolio in QUALCOMM Incorporated (NASDAQ:QCOM). Alps Advsrs holds 747,034 shares or 0.33% of its portfolio. M&T Bancshares invested in 0.43% or 1.30 million shares.

The stock increased 1.68% or $1.86 during the last trading session, reaching $112.36. About 369,262 shares traded. United Therapeutics Corporation (NASDAQ:UTHR) has declined 23.69% since March 30, 2017 and is downtrending. It has underperformed by 35.24% the S&P500.

Investors sentiment increased to 1.14 in Q4 2017. Its up 0.15, from 0.99 in 2017Q3. It improved, as 26 investors sold United Therapeutics Corporation shares while 112 reduced holdings. 53 funds opened positions while 105 raised stakes. 40.90 million shares or 1.42% less from 41.49 million shares in 2017Q3 were reported. Credit Suisse Ag accumulated 0.02% or 118,252 shares. Nomura Asset Mngmt Limited accumulated 13,549 shares. Jane Street Grp Limited Co holds 1,462 shares. Cibc Asset Management Inc reported 1,490 shares. 2,238 were accumulated by M&T Comml Bank. Moreover, Gsa Ptnrs Llp has 0.2% invested in United Therapeutics Corporation (NASDAQ:UTHR). Oregon Pub Employees Retirement Fund invested 0.06% in United Therapeutics Corporation (NASDAQ:UTHR). Commonwealth Of Pennsylvania Pub School Empls Retrmt holds 0.01% or 6,312 shares in its portfolio. Manufacturers Life The invested in 71,717 shares or 0.01% of the stock. Rafferty Asset Mngmt Ltd holds 0.07% or 27,456 shares. Teachers Retirement Systems Of The State Of Kentucky has 9,850 shares for 0.02% of their portfolio. Hsbc Public Lc, United Kingdom-based fund reported 63,063 shares. 522,093 are owned by First Trust Advsr Lp. Nuwave Investment Limited Liability Corporation stated it has 0% in United Therapeutics Corporation (NASDAQ:UTHR). Oak Associates Limited Oh holds 4,545 shares.

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company has market cap of $4.86 billion. The company's product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It has a 12.07 P/E ratio. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy.

Among 12 analysts covering United Therapeutics (NASDAQ:UTHR), 2 have Buy rating, 4 Sell and 6 Hold. Therefore 17% are positive. United Therapeutics has $244 highest and $95.0 lowest target. $144.50’s average target is 28.60% above currents $112.36 stock price. United Therapeutics had 31 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Hold” rating by H.C. Wainwright given on Thursday, October 26. As per Friday, July 28, the company rating was maintained by H.C. Wainwright. Jefferies maintained the stock with “Sell” rating in Thursday, September 14 report. The rating was maintained by Oppenheimer on Sunday, July 30 with “Buy”. The stock has “Buy” rating by Ladenburg Thalmann on Friday, October 28. On Monday, November 13 the stock rating was maintained by Wedbush with “Buy”. Cowen & Co maintained the shares of UTHR in report on Thursday, July 27 with “Hold” rating. The company was maintained on Tuesday, July 18 by Oppenheimer. The stock has “Hold” rating by Argus Research on Tuesday, May 24. As per Thursday, February 22, the company rating was maintained by Credit Suisse.

Martine Rothblatt, the Chairman & CEO of United Therapeutics Corp, made a sale of 43,024 shares of the company, worth $4,781,811 US Dollars, based on a market price of $111.1 a share. It seems she is very active lately as in the last 30 days, she silently unloaded additional 87,950 shares of the company, worth $9,778,159 USD. The chance of this transaction remaining unseen is extremely low as it’s significant, with Martine Rothblatt now owning 683,629 shares —- that is 1.58% of United Therapeutics Corp’s market cap.

Since October 5, 2017, it had 0 insider purchases, and 10 selling transactions for $10.46 million activity. 1,263 United Therapeutics Corporation (NASDAQ:UTHR) shares with value of $151,813 were sold by ROTHBLATT MARTINE A. Shares for $70,760 were sold by CAUSEY CHRISTOPHER.

Analysts await United Therapeutics Corporation (NASDAQ:UTHR) to report earnings on April, 25. They expect $3.64 earnings per share, down 6.43% or $0.25 from last year’s $3.89 per share. UTHR’s profit will be $157.38 million for 7.72 P/E if the $3.64 EPS becomes a reality. After $2.06 actual earnings per share reported by United Therapeutics Corporation for the previous quarter, Wall Street now forecasts 76.70% EPS growth.

United Therapeutics Corporation (NASDAQ:UTHR) Institutional Positions Chart